203 related articles for article (PubMed ID: 1578128)
1. Inhibition of class I and class II MHC-restricted antigen presentation by cytotoxic T lymphocytes specific for an exogenous antigen.
Rock KL; Rothstein L; Fleischacker C; Gamble S
J Immunol; 1992 May; 148(10):3028-33. PubMed ID: 1578128
[TBL] [Abstract][Full Text] [Related]
2. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules.
Rock KL; Rothstein L; Gamble S; Fleischacker C
J Immunol; 1993 Jan; 150(2):438-46. PubMed ID: 8419476
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.
Rock KL; Clark K
J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907
[TBL] [Abstract][Full Text] [Related]
4. MHC class I-restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo.
Grant EP; Rock KL
J Immunol; 1992 Jan; 148(1):13-8. PubMed ID: 1727862
[TBL] [Abstract][Full Text] [Related]
5. Presentation of exogenous antigens by macrophages: analysis of major histocompatibility complex class I and II presentation and regulation by cytokines.
Kovacsovics-Bankowski M; Rock KL
Eur J Immunol; 1994 Oct; 24(10):2421-8. PubMed ID: 7925570
[TBL] [Abstract][Full Text] [Related]
6. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.
Kern DE; Klarnet JP; Jensen MC; Greenberg PD
J Immunol; 1986 Jun; 136(11):4303-10. PubMed ID: 2422280
[TBL] [Abstract][Full Text] [Related]
7. Weak base amines can inhibit class I MHC-restricted antigen presentation.
Michalek MT; Benacerraf B; Rock KL
J Immunol; 1991 Jan; 146(2):449-56. PubMed ID: 1987272
[TBL] [Abstract][Full Text] [Related]
8. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
9. Activation of MHC class I-restricted CD8+ CTL by microbial T cell mitogens. Dependence upon MHC class II expression of the target cells and V beta usage of the responder T cells.
Herrmann T; Maryanski JL; Romero P; Fleischer B; MacDonald HR
J Immunol; 1990 Feb; 144(4):1181-6. PubMed ID: 1968075
[TBL] [Abstract][Full Text] [Related]
10. The class II MHC-restricted presentation of endogenously synthesized ovalbumin displays clonal variation, requires endosomal/lysosomal processing, and is up-regulated by heat shock.
Michalek MT; Benacerraf B; Rock KL
J Immunol; 1992 Feb; 148(4):1016-24. PubMed ID: 1737924
[TBL] [Abstract][Full Text] [Related]
11. Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses.
Ke Y; Li Y; Kapp JA
Eur J Immunol; 1995 Feb; 25(2):549-53. PubMed ID: 7875219
[TBL] [Abstract][Full Text] [Related]
12. Class I-restricted presentation occurs without internalization or processing of exogenous antigenic peptides.
Hosken NA; Bevan MJ; Carbone FR
J Immunol; 1989 Feb; 142(4):1079-83. PubMed ID: 2492575
[TBL] [Abstract][Full Text] [Related]
13. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
Tomita Y; Mayumi H; Eto M; Nomoto K
J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
[TBL] [Abstract][Full Text] [Related]
14. Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer.
Yokouchi H; Chamoto K; Wakita D; Noguchi D; Yamazaki K; Dosaka-Akita H; Nishimura M; Ikeda H; Nishimura T
Cancer Sci; 2006 Feb; 97(2):148-54. PubMed ID: 16441426
[TBL] [Abstract][Full Text] [Related]
15. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
16. Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo.
Ishioka GY; Colon S; Miles C; Grey HM; Chesnut RW
J Immunol; 1989 Aug; 143(4):1094-100. PubMed ID: 2787356
[TBL] [Abstract][Full Text] [Related]
17. A mutant antigen-presenting cell defective in antigen presentation expresses class II MHC molecules with an altered conformation.
Dang LH; Lien LL; Benacerraf B; Rock KL
J Immunol; 1993 May; 150(10):4206-17. PubMed ID: 8482833
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 envelope protein is expressed on the surface of infected cells before its processing and presentation to class II-restricted T lymphocytes.
Callahan KM; Rowell JF; Soloski MJ; Machamer CE; Siliciano RF
J Immunol; 1993 Sep; 151(6):2928-42. PubMed ID: 8376762
[TBL] [Abstract][Full Text] [Related]
19. Cytolytic T lymphocytes from the BALB/c-H-2dm2 mouse recognize the vesicular stomatitis virus glycoprotein and are restricted by class II MHC antigens.
Browning MJ; Huang AS; Reiss CS
J Immunol; 1990 Aug; 145(3):985-94. PubMed ID: 1695651
[TBL] [Abstract][Full Text] [Related]
20. The predominance of CD8+ T cells after infection with measles virus suggests a role for CD8+ class I MHC-restricted cytotoxic T lymphocytes (CTL) in recovery from measles. Clonal analyses of human CD8+ class I MHC-restricted CTL.
van Binnendijk RS; Poelen MC; Kuijpers KC; Osterhaus AD; Uytdehaag FG
J Immunol; 1990 Mar; 144(6):2394-9. PubMed ID: 2107259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
